The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin

Thromb Res. 2020 Dec:196:395-397. doi: 10.1016/j.thromres.2020.09.024. Epub 2020 Sep 17.
No abstract available

Keywords: Anricoagulation; COVID-19; Coagulopathy; Enoxaparin; Fondaparinux; Hemorrhage; Low-molecular-weight heparin; Thrombosis; Venous thromboembolism.

Publication types

  • Comparative Study
  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / adverse effects*
  • COVID-19 / complications
  • COVID-19 / diagnosis
  • COVID-19 Drug Treatment*
  • Enoxaparin / adverse effects*
  • Factor Xa Inhibitors / adverse effects*
  • Female
  • Fondaparinux / adverse effects*
  • Hemorrhage / chemically induced*
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Thrombosis / diagnosis
  • Thrombosis / etiology
  • Thrombosis / prevention & control*
  • Treatment Outcome
  • Venous Thromboembolism / diagnosis
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control*

Substances

  • Anticoagulants
  • Enoxaparin
  • Factor Xa Inhibitors
  • Fondaparinux